CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study

• DOI: 10.2337/dc22-1297
• Publication Date: 2023-02-02T19:09:15Z
• Authors: Darrell M. Wilson; Susan L. Pietropaolo; Maria Acevedo-Calado; Shuai Huang; Destiny Anyaiwe; David Scheinker; Andrea K. Steck; Madhuri M. Vasudevan; Siripoom V. McKay; Jennifer L. Sherr; Kevan C. Herold; Jessica L. Dunne; Carla J. Greenbaum; Sandra M. Lord; Michael J. Haller; Desmond A. Schatz; Mark A. Atkinson; Patrick W. Nelson; Massimo Pietropaolo
• Keywords: Male; Blood Glucose; 03 medical and health sciences; Diabetes Mellitus, Type 1; Glucose; 0302 clinical medicine; Adolescent; Blood Glucose Self-Monitoring; Humans; Female; Autoantibodies

OBJECTIVE Continuous glucose monitoring (CGM) parameters may identify individuals at risk for progression to overt type 1 diabetes. We aimed determine whether CGM metrics provide additional insights into clinical stage 3 RESEARCH DESIGN AND METHODS One hundred five relatives of in diabetes probands (median age 16.8 years; 89% non-Hispanic White; 43.8% female) from the TrialNet Pathway Prevention study underwent 7-day assessments and oral tolerance tests (OGTTs) 6-month intervals. The baseline data are reported here. Three groups were evaluated: with 1) 2 (n = 42) two or more diabetes-related autoantibodies abnormal OGTT; 2) 53) normal 3) negative test all OGTT 10). RESULTS Multiple associated Specifically, spending ≥5% time levels ≥140 mg/dL (P 0.01), ≥8% 0.02), ≥160 0.0001), 0.02) disease. Stage participants those who progressed also exhibited higher mean daytime values; spent values over 120, 140, 160 mg/dL; had greater variability. CONCLUSIONS could aid identification individuals, including a OGTT, likely rapidly progress